Decreased sensitivity to benzodiazepine receptor agonists and increased sensitivity to inverse agonists following chronic treatments: evidence for separate mechanisms.
Stephens
D N
DN
Neuropsychopharmacology, Schering AG, Berlin, F.R.G.
Schneider
H H
HH
Weidmann
R
R
Zimmermann
L
L
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001067:Appetite Depressants / Q000494:pharmacology; D001569:Benzodiazepines; D002243:Carbolines / Q000494:pharmacology; D002712:Chlorides / Q000378:metabolism; D003975:Diazepam / Q000494:pharmacology; D004347:Drug Interactions; D004361:Drug Tolerance; D005106:Exploratory Behavior / Q000187:drug effects; D007473:Ion Channels / Q000378:metabolism; D007696:Kindling, Neurologic / Q000187:drug effects*; D008124:Locomotion / Q000187:drug effects; D008140:Lorazepam / Q000031:analogs & derivatives / Q000378:metabolism; D051379:Mice; D009118:Muscimol / Q000378:metabolism; D010433:Pentylenetetrazole / Q000494:pharmacology; D051381:Rats; D011963:Receptors, GABA-A / Q000187:drug effects*
D014151:Anti-Anxiety Agents; D001067:Appetite Depressants; D002243:Carbolines; D002712:Chlorides; D007473:Ion Channels; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D009118:Muscimol; C035874:FG 7142; C023842:lormetazepam; D008140:Lorazepam; D003975:Diazepam; D010433:Pentylenetetrazole